Keytruda Denied by Insurance?
How to Appeal & Get Approved
Generic: pembrolizumab
The most widely used cancer immunotherapy — denied when biomarker documentation is missing.
- Used for
- NSCLC, Melanoma, Head/Neck, Bladder, MSI-H solid tumors, +15 indications
- Route
- IV
- Specialty
- Oncology
- PA Required
- Yes — 87% of prescriptions
Common Denial Reasons
Keytruda is frequently denied for step therapy, documentation, and formulary reasons. Decode your specific denial →
require prior authorization before your pharmacy can fill them. If you've been denied, you're not alone — and most denials can be overturned on appeal.
Step Therapy Requirements
"Fail first" — what insurers require before approving Keytruda
Most insurers require you to try alternative medications before approving Keytruda. See your insurer's requirements →
Let Ellen Fight Your Keytruda Denial
Ellen generates a personalized appeal letter for Keytruda using your denial reason, insurer, and clinical situation.
- ✓Instant denial decoding — understand why you were denied
- ✓Payer-specific appeal language that matches your insurer's criteria
- ✓Clinical evidence suggestions your doctor can use
Insurance Coverage
Ellen tracks Keytruda coverage across 37+ major insurers including formulary status, step therapy requirements, and common denial patterns.
Check your insurer's Keytrudapolicy →Safety Information
From FDA-approved prescribing information for Keytruda (PD-1 Inhibitor (Immune Checkpoint))
Do Not Use If
- ✕Clinically significant hypersensitivity to pembrolizumab
Key Warnings
- ⚠Immune-mediated adverse events in any organ system — pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, skin reactions
- ⚠Monitor thyroid function, liver enzymes, renal function at baseline and periodically
- ⚠May require high-dose corticosteroids for immune-mediated toxicity
- ⚠Withhold or permanently discontinue based on severity of immune-mediated reactions
This is not a complete list. See the full Keytruda prescribing information or ask your pharmacist for comprehensive safety data.
Frequently Asked Questions
›Why was Keytruda denied for my cancer?
The most common reason is missing biomarker documentation. Keytruda requires PD-L1 testing (using the Dako 22C3 companion diagnostic) or MSI-H/dMMR status for most indications. Without these test results submitted with the PA, denial is almost automatic.
›Is Keytruda covered by insurance?
Keytruda is covered by most plans for FDA-approved indications with proper documentation. As a Protected Class drug (oncology), insurers face legal restrictions on denying cancer therapies — but they can and do deny for missing documentation.
›How do I expedite a Keytruda appeal?
Use the words 'Rapid Disease Progression' and 'Clinical Urgency: Life-Threatening Malignancy' when requesting expedited review. Your oncologist should request a peer-to-peer call and cite the NCCN Category 1 recommendation for your specific tumor type.
›Can my oncologist do a peer-to-peer for Keytruda?
Yes, and they should. Peer-to-peer reviews for oncology drugs have a high overturn rate. Have your oncologist cite KEYNOTE trial data specific to your cancer type and reference the NCCN Compendium listing.